Nanobiotix (NASDAQ:NBTX) Stock Price Down 5.7% – Time to Sell?
by Jessica Moore · The Cerbat GemNanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Get Free Report) shares traded down 5.7% during mid-day trading on Wednesday . The stock traded as low as $43.23 and last traded at $43.5850. 25,847 shares changed hands during mid-day trading, a decline of 56% from the average session volume of 59,378 shares. The stock had previously closed at $46.20.
Wall Street Analyst Weigh In
Several analysts have issued reports on the company. HC Wainwright restated a “buy” rating on shares of Nanobiotix in a research note on Monday. UBS Group upped their price target on shares of Nanobiotix from $3.50 to $30.00 and gave the company a “neutral” rating in a research note on Friday, May 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a research note on Tuesday, April 21st. Guggenheim upped their price target on shares of Nanobiotix from $26.00 to $36.00 and gave the company a “buy” rating in a research note on Thursday, April 2nd. Finally, TD Cowen restated a “buy” rating on shares of Nanobiotix in a research note on Thursday, March 12th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $26.67.
Get Our Latest Analysis on Nanobiotix
Nanobiotix Stock Down 7.4%
The firm has a 50 day simple moving average of $35.60 and a 200 day simple moving average of $27.24.
Nanobiotix (NASDAQ:NBTX – Get Free Report) last released its quarterly earnings results on Sunday, February 15th. The company reported ($0.23) EPS for the quarter. The firm had revenue of $3.42 million for the quarter. On average, equities analysts expect that Nanobiotix S.A. – Sponsored ADR will post 0.53 earnings per share for the current year.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the stock. Royal Bank of Canada grew its position in Nanobiotix by 2,000.0% in the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after acquiring an additional 2,500 shares in the last quarter. Optiver Holding B.V. purchased a new position in Nanobiotix in the third quarter worth $101,000. Marshall Wace LLP purchased a new position in Nanobiotix in the fourth quarter worth $220,000. Finally, Millennium Management LLC purchased a new position in Nanobiotix in the fourth quarter worth $390,000. 38.81% of the stock is currently owned by institutional investors.
Nanobiotix Company Profile
Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.
Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.